We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -72.00 | -0.58% | 12,246.00 | 12,252.00 | 12,256.00 | 12,406.00 | 12,250.00 | 12,324.00 | 6,022,043 | 16:35:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.90 | 189.96B |
From May 2019 to May 2024
By Colin Kellaher
AstraZeneca PLC and Merck & Co. Monday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of two additional indications for the cancer drug Lynparza.
The drugmakers said one recommendation covers Lynparza as monotherapy for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed following a prior therapy that included a new hormonal agent.
The second recommendation covers Lynparza as a first-line maintenance treatment in combination with bevacizumab for HRD-positive advanced ovarian cancer.
The indications now await approval from the European Commission, which generally follows the CHMP's recommendations.
AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 21, 2020 10:27 ET (14:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
